6 results match your criteria: "Airway Institute in Sendai Co.[Affiliation]"
Asthma exacerbations in patients with asthma and rhinitis: Factors associated with asthma exacerbation and its effect on QOL in patients with asthma and rhinitis.
Allergol Int
October 2019
Airway Institute in Sendai Co., Ltd., Miyagi, Japan.
Background: The comorbidity of asthma and allergic rhinitis is remarkably high, but not much is known about the effects of this combined condition on the quality of life. We aimed to evaluate the factors associated with asthma exacerbations and the effect of the exacerbations on the quality of life (QOL) through a one-year, large-scale, observational study in Japanese patients with asthma and rhinitis.
Methods: A case survey by attending physicians and a patient survey was conducted at each assessment timepoint over a period of one year.
Comparison of the aerosol velocity of two Respimat soft mist inhalers and two pressurized metered-dose inhalers for short-acting muscarinic antagonists.
Respir Investig
July 2017
Airway Institute in Sendai Co., Ltd., 4-2-11 Hachiman Aoba-ku, Sendai 980-0871, Japan. Electronic address:
Comparison of the aerosol velocity of Respimat® soft mist inhaler and seven pressurized metered dose inhalers.
Allergol Int
October 2015
Airway Institute in Sendai Co., Limited, Miyagi, Japan. Electronic address:
Transdermal tulobuterol patch, a long-actingβ(2)-agonist.
Allergol Int
June 2012
Airway Institute in Sendai Co., Ltd., Miyagi, Japan.
Tulobuterol patch (HokunalinTM Tape), which contains a β(2)-adrenergic agonist, is the first bronchodilator to be available as a transdermal patch. This drug delivery system ensures that the time at which the peak drug concentration in the blood is reached coincides with the morning dip in respiratory function. The use of the patch also prevents excessive increase in blood drug concentrations, thereby reducing the incidence of systemic adverse reactions.
View Article and Find Full Text PDFIn vitro evaluation of dry powder inhaler devices of corticosteroid preparations.
Allergol Int
March 2012
Airway Institute in Sendai Co., Ltd., Sendai, Miyagi, Japan.
Background: Although investigations of the drug aerosols generated from inhaled corticosteroid (ICS) preparations and combined drug preparations provide basic information about inhalation therapy, many clinicians have one-sided data about the precision of drug aerosols from the manufacturer. The present study was conducted to analyze and compare the performances of dry powder inhaler (DPI) devices of ICS and combined drug preparations.
Methods: The particle size of individual aerosols was measured according to the time-of-flight principle in terms of their aerodynamic diameter by using the aerodynamic particle sizer spectrometer Model 3321.
Purpose: To evaluate the performances of various devices for inhaled steroid.
Methods: Aerosol particle diameters were determined using the Aerodynamic Particle Sizer Spectrometer. Conversion ratios to fine particle aerosol were determined using an Andersen non-bubble sampler.